Formulation Development of a Polymer-Drug Matrix with a Controlled Release Profile for the Treatment of Glaucoma

<p>Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.</p>

Name thesis:degree_name

MS in Polymers and Coatings

Discipline thesis:degree_discipline

Chemistry & Biochemistry

Year dc:date.available

2013

Author dc:creator

• Tsoi, Eric W.

Contributors dc:contributor

• Raymond Fernando

• Formulation
• Polymer
• Controlled Release
• Glaucoma
• Biomedical Devices and Instrumentation
• Pharmaceutical Preparations
• Polymer Chemistry

Identifier

10.15368/theses.2013.214

OAI identifier oai:identifier

oai:digitalcommons.calpoly.edu:theses-2239